Get our premium offer's for 20% discount Contact Us View Cart!

UK Makes Medical History as First Patient Receives New Drug to Delay Type 1 Diabetes

Annette Quilter makes UK medical history as the first NHS patient to receive Teplizumab, a pioneering treatment that can delay Type 1 diabetes.

A pioneering treatment has been administered to its first NHS patient in the UK, giving fresh hope to people at risk of progressing to insulin-dependent Type 1 diabetes.

A new chapter in diabetes treatment has begun in the United Kingdom after 42-year-old Annette Quilter became the first patient in the country to receive Teplizumab through the National Health Service (NHS).

Annette, a mother of three and general practitioner from Shropshire, received the pioneering treatment at Queen Elizabeth Hospital Birmingham (QEHB) during the first week of November 2026.



Her treatment marks an important milestone for people living with early-stage Type 1 diabetes, as Teplizumab offers something that has not previously been available through this type of treatment: an opportunity to slow the progression of the disease before patients reach the stage where they require insulin.

For Annette, the development is particularly meaningful. Following her Stage 2 Type 1 diabetes diagnosis during the summer, she was identified as suitable for the treatment after undergoing specialist screening and assessment.

She described the diagnosis as a shock but said the opportunity to receive the new medication had given her some relief.

With three young children and a demanding career as a GP, she explained that having additional time to prepare for the daily responsibilities of managing diabetes would mean a great deal to her family and personal life.

What Is Teplizumab and How Does It Work?

Teplizumab, also known by its brand name Tzield, is a groundbreaking immunotherapy developed to slow the progression of Type 1 diabetes in people identified at an early stage.

To understand why this treatment matters, it is important to understand what happens inside the body when someone develops Type 1 diabetes.

Type 1 diabetes is an autoimmune condition. This means the body's immune system mistakenly attacks its own healthy cells.

In this case, the immune system targets the insulin-producing beta cells found in the pancreas. These cells are responsible for producing insulin, a hormone that helps regulate blood sugar levels.

As the attack continues, the pancreas gradually loses its ability to produce enough insulin. Eventually, patients require insulin treatment to manage their blood glucose levels.

Teplizumab works by modifying the activity of certain immune cells responsible for attacking these insulin-producing cells. By slowing down this process, the drug can help preserve the remaining cells for longer.

This does not mean the disease is cured. Instead, it gives eligible patients additional time before the condition progresses to the stage where symptoms become apparent and insulin treatment is needed.

How Much Time Can the New Treatment Buy Patients?

One of the most encouraging findings from clinical research is that Teplizumab can delay the progression to symptomatic Type 1 diabetes by an average of nearly three years.

Evidence reviewed by the UK's National Institute for Health and Care Excellence (NICE) found that the treatment delayed the development of symptomatic disease by approximately 32 months in the landmark clinical trial.

However, the results will not be identical for everybody. Some patients may experience a shorter delay, while others may benefit for longer.

Even so, the additional time could make a significant difference, particularly for children and young adults who may otherwise have to adjust to insulin treatment at an early stage of life.

It could also provide families with more time to understand the condition, receive medical guidance and prepare for the changes that come with managing diabetes.

How Is Teplizumab Administered?

Unlike everyday diabetes medications, Teplizumab is administered through an intravenous infusion, meaning the medication is delivered directly into a patient's bloodstream through a drip.

The treatment involves one infusion daily for 14 consecutive days.

Each infusion takes approximately 30 minutes, although patients also need to remain under medical observation afterwards.

Annette's treatment at Queen Elizabeth Hospital Birmingham is being delivered by specialist clinical and infusion nursing teams, working alongside pharmacy professionals.

The hospital's achievement follows years of medical research and collaboration involving healthcare professionals and academics working to improve the treatment of Type 1 diabetes.

Who Can Receive the Treatment?

Teplizumab is not designed for everybody living with diabetes.

In the UK, it has been approved for eligible adults and children aged eight and above who have Stage 2 Type 1 diabetes.

Stage 2 is an early phase of the condition. At this point, blood tests can show that the immune system is attacking insulin-producing cells and that blood sugar regulation is beginning to change, even though the person may not yet have noticeable symptoms.

Specialist blood tests and medical assessments are therefore important in identifying people who could benefit.

The NHS approval followed a recommendation by NICE in June 2026, making the treatment available through NHS services in England and Wales for people who meet the clinical eligibility requirements.

Is This a Cure for Type 1 Diabetes?

Despite the excitement surrounding the development, it is important to understand what Teplizumab can and cannot do.

The drug is not a cure for Type 1 diabetes. It does not permanently stop the immune system from attacking insulin-producing cells, nor does it guarantee that a patient will never need insulin.

Its main purpose is to slow the progression of the disease and delay the point at which insulin treatment becomes necessary.

Nevertheless, this represents a major development in diabetes research because it moves treatment beyond simply managing blood sugar levels after the disease has progressed.

Instead, doctors now have an approved option that can intervene earlier in the disease process.

A New Direction for Diabetes Research

Annette Quilter's treatment is more than an individual medical milestone. It represents progress in the wider effort to understand, identify and manage autoimmune diseases before they cause more serious damage.

For years, people diagnosed with Type 1 diabetes have depended on insulin therapy to manage a condition that requires lifelong attention.

The introduction of Teplizumab provides another option for a specific group of patients and opens the door to further research into treatments that target the immune system itself.

There is still work to be done, particularly in expanding early screening, improving access and understanding how patients respond to the treatment over time.

But for Annette and other eligible patients, having additional time before insulin becomes necessary is already a meaningful step forward.

Medical Disclaimer: This article is for general information and educational purposes. Teplizumab is a specialist treatment with specific eligibility requirements. Anyone concerned about Type 1 diabetes or interested in early screening should speak with a qualified healthcare professional.

Featured products See all

About the Author

🎭 Actor | 💻 Web & Graphic Designer | 🎬 Video Editor | 🎬 Crafting stories on-screen and building brands online. https://youtube.com/@MrOshimiriofficial
– Posts – Comments

Don't miss out

Subscribe to get our latest posts straight to your inbox

إرسال تعليق

Cookie Consent
We serve cookies on this site to analyze traffic, remember your preferences, and optimize your experience.
Oops!
It seems there is something wrong with your internet connection. Please connect to the internet and start browsing again.
AdBlock Detected!
We have detected that you are using adblocking plugin in your browser.
The revenue we earn by the advertisements is used to manage this website, we request you to whitelist our website in your adblocking plugin.
Site is Blocked
Sorry! This site is not available in your country.